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ABSTRACT	
In	2014,	a	joint	task	force	involving	the	European	Society	of	Cardiology	and	European	
Society	of	Anaesthesiology,	assembled	‘Guidelines	on	non-cardiac	surgery:	cardiovascular	
assessment	and	management’.		The	guidelines,	subsequently	published	in	the	European	
Heart	Journal,	are	intended	for	physicians	and	collaborators	involved	in	the	perioperative	
care	of	patients	undergoing	non-cardiac	surgery,	in	whom	heart	disease	is	a	potential	source	
of	complications.		Whilst	the	guidelines	are	therefore	an	extremely	relevant	and	useful	aid	
for	most,	if	not	all,	medics	within	the	hospital	environment,	the	sheer	size	of	the	document	
(49	pages)	renders	it	a	feat	to	read	and	digest.		Given	the	importance	of	the	document	for	
optimising	patient	care,	we	have	condensed	the	guidelines	down	to	facilitate	familiarisation	
of	a	number	of	the	important	details.		
	
	
KEY	POINTS	
1. The	incidence	of	cardiac	complications	after	non-cardiac	surgery	depends	on	the	
interaction	between	the	type	of	surgery	and	the	circumstances	under	which	it	
occurs,	and	patient-related	risk	factors.		
2. Surgical	interventions	can	be	divided	into	those	associated	with	low-,	intermediate-	
and	high-cardiac	risk.	
3. Preoperative	cardiac	evaluation	must	be	tailored	to	the	patient	and	surgical	urgency.			
4. Cardiac	imaging	should	be	performed	only	where	results	would	influence	
management.	
5. Continuing	or	ceasing	dual	antiplatelet	therapy	in	those	with	coronary	stents,	must	
be	discussed	between	surgeon	and	cardiologist,	weighing	risk	of	surgical	bleeding	
against	life-threatening	stent	thrombosis.	
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INTRODUCTION	
The	European	Society	of	Cardiology	and	European	Society	of	Anaesthesiology	‘Guidelines	on	
non-cardiac	surgery:	cardiovascular	assessment	and	management’(Kristensen	et	al,2014),	
are	an	extremely	relevant	aid	for	all	hospital	medics.	Herewith,	we	provide	a	markedly	
abridged	version	to	accompany,	but	not	replace	them.	
	
The	incidence	of	cardiac	complications	after	non-cardiac	surgery	depends	on	surgery	type	
and	circumstance,	and	patient-related	risk	factors.		
	
	
TYPE	OF	SURGERY	REQUIRED	
	
Surgical	interventions	can	be	classified	as	being	associated	with	low,	intermediate	and	high	
cardiac	risk	(CR)	(<1%,	1–5%,	and	>5%	30-day	risk	of	cardiac	death	and	myocardial	infarction	
respectively,	(Table	1)).		
	
Vascular	surgery	is	’high-risk’,	especially	infra-inguinal	revascularisation,	whose	risk	is	
greater	than	that	of	aortic	procedures	–	perhaps	due	to	patients’	advanced	age	and	high	
incidence	of	diabetes,	renal	dysfunction	and	ischaemic	heart	disease	(IHD).		
Laparoscopic/endoscopic/endovascular	techniques	generally	confer	lower	CR	than	‘open’	
alternatives,	however	older,	sicker,	and	’urgent’	patients	featured	more	frequently	in	the	
‘open’	cohorts	leading	to	possible	bias.		Importantly	debilitated	patients,	and	those	with	
cardiac	disease,	may	tolerate	pneumoperitoneum/Trendelenburg	position	less	well.		
	
	
PATIENT	RELATED	RISK	FACTORS	
Preoperative	cardiac	evaluation	must	be	tailored	to	the	patient/surgical	urgency.		After	
comprehensive	history-taking	and	examination,	including	assessment	of	functional	capacity	
and	risk	indices	(below),	most	‘low	CR’	patients	can	undergo	low-	and	intermediate-risk	
surgery	without	delay	-	risk	isn’t	significantly	reduced	by	pharmacological	intervention.		
Cardiac	imaging	should	be	performed	only	where	results	would	influence	management.		
	i)	Functional	capacity		
Functional	capacity	is	assessed	objectively	through	exercise	testing,	but	estimated	from	the	
‘metabolic	equivalents’	(METs)	of	normal	activities	(one	MET	=basal	metabolic	rate	at	rest;	4	
METs	=climbing	two	flights	of	stairs;	10	METs	=strenuous	sports)	(Fletcher	et	al,2001).	
Inability	to	run	a	short	distance/climb	two	flights	of	stairs	(<4	METs)	indicates	poor	
functional	capacity	and	raised	perioperative	CR.	Risk	is	low	when	functional	capacity	is	high,	
even	in	the	presence	of	stable	IHD	or	other	risk	factors.		
	
ii)	Risk	indices	
‘Lee’s	revised	CR	index’	(Lee	et	al,1999)	includes	six	variables:	type	of	surgery,	and	presence	
of	IHD/heart	failure/cerebrovascular	disease/renal	failure	(creatinine	>170mmol/L)/insulin-
dependent	diabetes.	The	American	College	of	Surgeons	National	Surgical	Quality	
Improvement	Program	database	(Gupta	et	al,2011)	uses	five	predictors	of	myocardial	
infarction/cardiac	arrest:	age/American	Society	of	Anesthesiologists	(ASA)	class/type	of	
surgery/functional	status/elevated	creatinine	(>130mmol/L).	
	
iii)	Biomarkers	
These	can	suggest	myocardial	injury	(cardiac	troponins	T	and	I)	or	left	ventricular	
dysfunction	(B-type	natriuretic	peptide	(BNP)	and	N-terminal	pro-BNP	(NT-proBNP)).		Whilst	
small	perioperative	troponin	increases	reflect	poorer	cardiac	prognosis,	with	limited	data	
routine	biomarker	assessment	in	non-cardiac	surgery	isn’t	advised,	but	may	be	considered	
in	high-risk	patients.	
	
iv)	Non-invasive	testing	
Myocardial	ischaemia,	left	ventricular	dysfunction	and	heart	valve	abnormalities	are	major	
determinants	of	risk.	Pre-operative	non-invasive	testing	(e.g.	resting/stress	
echocardiography,	cardiopulmonary	exercise	testing,	myocardial	perfusion	imaging,	
cardiovascular	magnetic	resonance	imaging,	CT	angiography)	may	be	informative.		Risk	
stratification	and	investigation	should	be	similar	to	that	for	patients	in	the	non-surgical	
setting,	and	considered	if	coronary	artery	revascularisation	would	also	be	considered,	or	to	
help	inform	patient	choice/change	perioperative	management	(e.g.	type	of	surgery	or	
anaesthetic	technique).		
	
	
RISK-REDUCTION	STRATEGIES		
	
Pharmacological		
The	risk:benefit	profile	of	medicating	to	decrease	perioperative	CR	should	be	considered,	
and	contraindications	respected.	
	
Beta-blockers		
Cardiac	beta-receptor	antagonists	(beta-blockers)	decrease	myocardial	oxygen	consumption	
by	reducing	heart	rate	and	myocardial	contractility.	Data	from	trials	of	beta-blockers	use	to	
reduce	perioperative	cardiac	complications	are	conflicting	-	perhaps	due	to	differences	in	
patients,	surgery,	and	beta-blocker	type/timing	of	onset/duration/dose	titration.		Consensus	
however	is	that	beta-blockers	may	be	commenced	preoperatively	in	known	IHD.		Beta1-
selective	antagonists	without	intrinsic	sympathomimetic	activity	are	preferred,	with	
atenolol	and	bisoprolol	over	metoprolol.		Treatment	should	ideally	be	initiated	30days	(and	
>2days)	preoperatively,	dose	up-titrated	to	a	resting	heart	rate	of	60-70bpm	and	systolic	
blood	pressure	>100mmHg.	
	
Statins		
Statins	prevent	atheromatous	plaque	progression,	induce	their	regression	and	stabilise	
them.	Data	concerning	perioperative	statin	impact	on	all-cause/cardiovascular	mortality,	
and	myocardial	infarction	are	conflicting,	but	patients	with	peripheral	artery	disease	(PAD)	
should	receive	statins,	continued	after	vascular	surgery	or	endovascular	intervention.	Statin-
naive	PAD	patients	should	receive	them	starting-	>2weeks	prior	to	intervention,	and	
continuing	for	>1month	post-surgery.		Statin	withdrawal	>4days	following	aortic	surgery	is	
associated	with	a	three-fold	risk	of	post-operative	myocardial	ischaemia.	In	non-vascular	
surgery,	no	evidence	supports	pre-operative	statin	treatment	if	without	other	indications.		
	
Angiotensin-converting	enzyme	inhibitors(ACEIs)	and	angiotensin-receptor	blockers	
(ARBs)	
Their	use	until	the	day	of	surgery	is	associated	with	increased	risk	of	hypotension	under	
anaesthesia,	particularly	following	induction	and	if	simultaneously	taking	beta-blockers.		
Vasopressor	response	may	also	be	impaired.		They	should	thus	be	stopped	24hours	
preoperatively	when	prescribed	for	hypertension,	and	restarted	at	the	earliest	opportunity	
postoperatively.		In	heart	failure	and	systolic	LV	dysfunction,	ACEIs	should	be	continued	
perioperatively,	and	commencement	considered	for	those	not	already	taking	them.		
	
Calcium	channel	blockers		
Routine	use	of	dihydropyridines	and	non-dihydropyridines	is	not	recommended,	and	short	
acting	dihydropiridines	(especially	nifedipine	capsules)	should	be	avoided.		
	
Alpha2	receptor	agonists	or	nitrates		
Routine	perioperative	intravenous	nitroglycerine	use	conveys	no	benefit	in	non-cardiac	
surgery,	and	may	increase	haemodynamic	risk.		Alpha2	receptor	agonists	increase	risk	of	
hypotension/non-fatal	cardiac	arrest.	
	
Diuretics		
Diuretics	should	be	continued	until	the	day	of	surgery,	and	resumed	as	soon	as	possible	
afterwards	–	assuming	appropriate	dose	adjustment	and	volume	status	allows.	Serum	
electrolytes	should	be	monitored	and	corrected	appropriately.		
	
	
Perioperative	management	in	patients	taking	anti-platelet	agents	
	
Aspirin	
As	continuation	increases	bleeding	complication	risk	by	50%	(but	not	severity),	aspirin	may	
need	to	be	discontinued	for	>7days	before	certain	ophthalmological/neurosurgical/spinal	
operations.		In	subjects	at	risk	of	IHD,	aspirin	non-adherence/withdrawal	tripled	major	
adverse	cardiovascular	event	(MACE)	risk.	Low-dose	aspirin	use	in	non-cardiac	surgery	
should	therefore	be	individualised,	balancing	perioperative	bleeding/thrombotic	risk	against	
cardiovascular	benefit.		
	
Dual	anti-platelet	therapy		
Coronary	stenting	requires	post-procedural	dual	anti-platelet	therapy	(DAPT)	to	avoid	stent	
thrombosis.		Whenever	possible,	surgery	should	proceed	without	discontinuation	of	aspirin,	
with	elective	surgery	postponed	(and	DAPT	continued)	for	a	minimum	of;	4weeks	and	
ideally	<3months	after	bare	metal	stent	implantation,	6months	for	second-	and	third-
generation	drug	eluting	stents	(DES),	and	for	12months	for	first	generation	DES.		In	patients	
undergoing	myocardial	revascularisation	for	high-risk	acute	coronary	syndromes,	DAPT	is	
recommended	for	one	year	irrespective	of	stent	type.		If	surgery	can’t	be	delayed,	it	should	
be	undertaken	in	hospitals	where	24/7	cardiac	catheterisation	availability	allows	immediate	
treatment	of	stent	occlusion.		DAPT	management	must	be	discussed	between	surgeon	and	
cardiologist,	weighing	risk	of	surgical	bleeding	against	life-threatening	stent	thrombosis	(on	
or	off	DAPT	respectively).	Excessive	or	life-threatening	perioperative	bleeding	in	a	patient	
receiving	anti-platelet	therapy	should	be	treated	with	platelet	transfusion.	
	
	
Perioperative	management	in	patients	on	anticoagulants	
	
Here,	risk:benefit	ratio	must	be	calculated	on	an	individual	basis.		
	
Vitamin	K	antagonists		
In	low-risk	patients	with	international	normalised	ratio	(INR)	≤1.5,	surgery	can	usually	
proceed	safely	with	minimal	bleeding	risk.		In	those	with	high	thromboembolic	risk	(e.g.	
mechanical	prosthetic	heart	valves,	recent	venous	thromboembolism,	or	thrombophilia),	
stopping	vitamin	K	antagonists	(VKAs)	is	dangerous	and	these	patients	will	need	bridging	
therapy	with	unfractionated	heparin	(UFH)	or	therapeutic-dose	low	molecular	weight	
heparins	(LMWH).		Both	agents	have	advantages	and	disadvantages,	and	haematologists	
should	help	guide	choice	and	timings	of	starting,	stopping,	and	then	re-starting	bridging	
therapy.		Depending	on	type	of	surgery,	and	whether	adequate	haemostasis	has	been	
achieved,	VKAs	should	be	restarted	postoperatively,	normally	by	administering	150%	of	the	
pre-operative	maintenance	dose	for	two	consecutive	days.		The	maintenance	dose	should	
be	administrated	thereafter,	and	UFH/LMWH	continued	until	INR	returns	to	pre-operative	
therapeutic	levels.	
	
Non-vitamin	K	antagonist	oral	anticoagulants		
Non-vitamin	K	oral	anticoagulants	(NOACs)	have	short	biological	half-lives	and	a	well-
defined	‘on’	and	‘off’	action	providing	renal	function	is	normal.		‘Bridging’	to	surgery	is	thus	
generally	unnecessary,	and	postoperative	resumption	of	treatment	should	be	delayed	for	1-
2	(in	some	cases	3-5)	days,	until	post-surgical	bleeding	risk	is	diminished.		An	exception	is	
the	patient	with	high	thromboembolic	risk,	whose	surgical	intervention	is	delayed	for	
several	days.		Here,	stop	NOACs	for	2–3	times	their	respective	half-lives	prior	to	surgery	
considered	to	have	a	‘normal’	bleeding	risk,	and	4–5	times	the	half-lives	before	high	
bleeding	risk	procedures.		
	Reversal	of	anticoagulant	therapy		
Vitamin	K	antagonists		
If	anticoagulation	is	required	before	urgent	surgery	in	patients	on	VKAs,	low-dose	(2.5-5mg)	
iv	or	oral	vitamin	K	will	lower	INR	in	6-12hours.	Additional	administration	of	fresh-frozen	
plasma	or	prothrombin	complex	concentrate	(PCC)	will	offer	immediate	effect.	
Anticoagulant	effects	of	UFH/LMWH	are	usually	reversed	4-8hours	respectively	after	
stopping	treatment.		Protamine	sulphate	immediately	reverses	UFH	action	-	the	anti-Xa	
activity	of	LMWH	will	not	be	completely	neutralised	(maximum	50%).		
	
Non-vitamin	K	antagonist	oral	anticoagulants		
Bleeding	should	be	managed	with	symptomatic	and	supportive	measure	and	
haematological	advice	sought	early.	There	are	no	specific	NOAC	antidotes,	although	PCC,		
recombinant	factor	VIIa,	and	haemodialysis	may	offer	benefit.	
	
	
Revascularisation		
	
In	patients	with	known	or	suspected	IHD	scheduled	for	major	non-cardiac	surgery,	
indications	for	coronary	angiography	or	pre-operative	revascularisation	are	similar	to	those	
in	the	non-surgical	setting.		If	surgery	can	be	safely	delayed,	symptoms	of	myocardial	
ischaemia	should	be	fully	investigated	and	treated	beforehand.		Asymptomatic	(silent)	
myocardial	ischaemia	should	not	be	sought	before	non-cardiac	surgery	-	coronary	
angiography	and/or	revascularisation	prior	to	non-cardiac	surgery	confers	no	benefit	
beyond	optimal	medical	management.		
The	role	of	prophylactic	revascularisation	in	patients	with	non-ST	elevation	acute	coronary	
syndromes	(NSTE-ACS)	requiring	non-cardiac	surgery	isn’t	known.		If	surgery	can	be	safely	
delayed,	priority	should	be	given	to	NSTE-ACS	management.	Otherwise	balloon	angioplasty	
alone,	or	PCI	using	a	bare	metal	stent	or	new	generation	DES	may	be	considered.		
	
	
SPECIFIC	DISEASES		
	
Presence	of	the	following	conditions	increases	perioperative	cardiac	event	risk.	
	
i)	Chronic	heart	failure	with	reduced	or	preserved	left	ventricular	ejection	fraction	(HF-REF	
or	HF-PEF).			
HF-PEF	patients	are	more	likely	older,	female,	hypertensive	with	AF,	and	less	likely	to	have	
coronary	artery	disease.		Generally,	their	prognoses	are	also	better.		Similar	perioperative	
management	is	recommended	in	both,	including	assessment	of	LVEF,	general	clinical	status	
and	volume	overload.		Elevated	circulating	natriuretic	peptide	concentrations	correlate	with	
morbidity	and	mortality.		Routine	preoperative	transthoracic	echocardiography	(TTE)	should	
not	be	performed	in	all,	but	considered	in	patients	with	known	or	suspected	heart	failure	
and	in	high-risk	surgical	populations.		Overall	functional	capacity	and	cardiopulmonary	
reserve	are	best	assessed	through	cardiopulmonary	exercise	testing	-	anaerobic	thresholds	
of	<11	mlO2/kg/min	suggest	increased	perioperative	morbidity/mortality	(Guazzi	et	al,	
2012).			
For	patients	newly	diagnosed	with	heart	failure,	non-urgent	surgery	should	be	delayed	
>3months.		Heart	failure	medications	should	be	continued	throughout	the	perioperative	
period,	especially	beta-blockers.		In	general,	all	should	be	continued	until	the	day	of	surgery	
-	in	those	very	susceptible	to	perioperative	hypotension,	transient	discontinuation	on	the	
day	before	surgery	may	be	considered	(see	ACEI/ARB	section	above).	If	stopped,	all	heart	
failure	medications	should	be	restarted	as	soon	as	possible	postoperatively:	administration	
via	nasogastric	tube	or	bioequivalent	intravenous	doses	should	be	considered.		
	
ii)	Arterial	hypertension		
Patients	with	pre-existing	hypertension	more	commonly	demonstrate	profound	
hypotension	at	induction,	or	intra-operative	blood	pressure	lability.		As	a	decrease	in	BP	
>20mmHg	for	more	>1hour	is	a	risk	factor	for	postoperative	complications,	perioperative	BP	
should	be	maintained	70–100%	of	baseline,	avoiding	excessive	tachycardia.		
In	patients	with	preoperative	hypertension,	signs	of	organ	damage	should	be	sought.	In	
patients	with	grade	1	or	2	hypertension	(systolic	BP	<180mmHg;	diastolic	BP	<110mmHg),	
delaying	surgery	to	optimise	therapy	offers	no	benefit.	However,	in	such	cases,	
antihypertensive	medications	should	be	continued	during	the	perioperative	period.	
	
iii)	Valvular	heart	disease		
Any	patient	with	known	or	suspected	valvular	heart	disease	should	have	echocardiography	
to	determine	the	need	for	treatment	prior	to	surgery.		
	
Aortic	stenosis		
Severe	aortic	stenosis	(valve	area	<1.0cm2,	maximum	jet	velocity	>4m/sec,	and/or	mean	
aortic	pressure	gradient	≥40mmHg)	is	particular	high	risk.		If	symptomatic,	valve	
replacement	should	be	considered	before	elective	surgery.		For	those	at	high	risk	for	
valvular	surgery	or	where	replacement	is	contraindicated,	balloon	aortic	valvuloplasty	(BAV)	
or	transcatheter	aortic	valve	implantation	(TAVI)	may	be	considered.		In	asymptomatic	
patients,	non-cardiac	surgery	of	low/intermediate	risk	can	be	performed	safely	-	invasive	
haemodynamic	monitoring	and	avoiding	rapid	changes	in	volume	status	and	heart	rate	and	
rhythm	are	essential.	
	
Mitral	stenosis		
With	valve	area	>1.5cm2	or	in	asymptomatic	patients	with	significant	mitral	stenosis	(valve	
area	<1.5cm2)	and	systolic	pulmonary	artery	pressure	<50mmHg,	non-cardiac	surgery	can	be	
performed	with	low-risk	of	MACE.		With	significant	mitral	stenotic	signs	and	symptoms,	risk	
from	non-cardiac	surgery	is	significantly	higher	-	percutaneous	mitral	commissurotomy	(or	
open	surgical	repair)	should	be	considered	preoperatively.	
	
Primary	aortic	regurgitation	and	mitral	regurgitation		
In	severe	aortic	or	mitral	regurgitation,	LV	function	should	be	assessed.		If	preserved,	non-
cardiac	surgery	can	be	performed	without	additional	risk.		If	impaired	(<30%),	or	
symptomatic,	non-cardiac	surgery	should	be	performed	only	if	necessary.		Non-significant	
aortic	regurgitation	and	mitral	regurgitation	do	not	independently	increase	the	
cardiovascular	risk	during	non-cardiac	surgery.	
	
Patients	with	prosthetic	valve(s)		
Those	without	valvular/ventricular	dysfunction	can	undergo	non-cardiac	surgery	without	
additional	risk.	Oral	anticoagulants	are	temporarily	replaced	by	UFH	or	LMWH	at	
therapeutic	doses.	
	
iv)	Arrhythmias		
Their	discovery	mandates	preoperative	cardiological	review	and	appropriate	investigation,	
referring	to	appropriate	guidelines	(Yegnasubramanian,2016).	
	
v)	Renal	disease		
Impaired	renal	function	is	associated	with	adverse	post-operative	cardiovascular	outcomes,	
including	myocardial	infarction/stroke/progression	of	heart	failure.		Chronic	kidney	disease	
(CKD)	is	a	risk	factor	for	the	development	of	acute	kidney	injury	(AKI)	following	non-cardiac	
surgery:	estimated	glomerular	filtration	rate	(eGFR)	should	be	calculated	in	all	(a	value	of	
<60	mL/min/1.73m2	correlates	significantly	with	MACE)	and	proteinuria	assessed	(as	urinary	
albumin	–	creatinine	ratio).		AKI	risk	is	also	associated	with	age	>56years;	male	sex;	presence	
of	cardiac	failure,	ascites,	hypertension	or	diabetes;	or	emergency	or	intraperitoneal	
surgery.		Supportive	measures	(e.g.	maintenance	of	adequate	intra-vascular	volume,	use	of	
vasopressors,	avoidance	of	nephrotoxic	agents)	should	be	considered	in	all	at	risk.		
Strategies	to	prevent	AKI	caused	by	iodinated	contrast	(contrast-induced	AKI,	(CI-AKI))	
include	minimising	administered	volume,	using	less-nephrotoxic	agents,	provision	of	
prophylactic	renal-replacement	therapy,	and	use	of	pharmacological	agents	to	counteract	
contrast	nephrotoxicity.		Pre-procedural	hydration	with	intravenous	isotonic	fluids	is	the	
most	effective	method	of	reducing	the	risk	of	CI-AKI,	and	normal	saline	or	isotonic	sodium	
bicarbonate	(1.26%)	may	be	administered.		The	benefit	of	N-acetyl-cysteine	in	CI-AKI	
prophylaxis	remains	unproven.		
	
vi)	Cerebrovascular	disease		
Stroke	(usually	thromboembolic)	occurs	in	0.1%	of	non-cardiac	surgical	patients,	but	is	
associated	with	a	700%	increase	in	perioperative	mortality	(absolute	risk	>20%)	(Mashour	et	
al,2011).		Perioperative	arterial	hypotension	is	a	risk	factor,	as	is	withdrawal	of	
anticoagulation	for	atrial	fibrillation	(AF)	or	of	antiplatelet	agents	(in	those	with	
atheromatous	disease)	during	the	hypercoagulable	perioperative	state.	Patients	with	
symptoms	suggestive	of	transient	ischaemic	attack	(TIA)	or	stroke	in	the	preceding	six	
months	should	receive	pre-operative	neurological	consultation.		
For	those	with	symptomatic	carotid	artery	disease,	revascularisation	should	be	performed	
prior	to	other	surgery.	In	asymptomatic	patients	with	severe	carotid	occlusive	disease,	
carotidrevascularisation	is	more	for	the	long-term	preventionof	stroke	than	perioperative	
stroke	reduction	and	may	be	performed	before	or	after	the	planned	non-cardiac	surgery.		
Asides	from	revascularisation,	patients	with	carotid	stenosisbenefit	from	aggressive	
cardiovascular	risk-factor	modification,	and	in	the	perioperative	setting,	statins	should	be	
continued,	aspirin	and	beta-blockers	should	not	be	withdrawn	if	possible,	and	blood	
pressure	should	be	carefully	controlled.		
Any	patient	with	PAD	is	at	increased	risk	of	CVA	and	perioperative	acute	MI,	so	should	be	
thoroughly	assessed	and	investigated	for	IHD.		Routine	exercise	or	imaging	testing	isn’t	
warranted	in	the	absence	of	symptoms	or	other	risk	factors.	
	
vii)	Pulmonary	disease		
This	increases	perioperative	risk,	especially	of	post-operative	pulmonary	complications.		Risk	
is	particularly	high	in	smoking-related	lung	disease,	and	after	abdominal	or	thoracic	surgery.		
Chronic	obstructive	pulmonary	disease	(COPD)	and	obesity	hypoventilation	syndrome	(OHS)	
are	also	especially	associated	with	cardiovascular	pathology,	and	such	patients	(and	any	
with	pulmonary	artery	hypertension	(PAH))	require	CR	assessment.		
Independent	of	age,	gender,	and	smoking	history,	every	10%	decrease	in	forcedexpiratory	
volume	in	1	second	is	associated	with	a	30%	increase	in	cardiovascular	mortality	and	20%	
increase	in	non-fatal	coronary	events	(Sin	DD	et	al,2005).	COPD	is	also	a	risk	factor	forIHD,	
and	also	leads	to	cor-pulmonale	with	associated	right-heart	failure.	In	COPD,	perioperative	
cardiovascular	risk	must	be	assessed	and	managed,	and	pulmonary	function	optimised.		
Education	regarding	pre-operative	smoking	cessation	(>2months	before	surgery),	chest	
physiotherapy	and	lung	expansion	manoeuvres	is	advocated,	as	may	be	muscular	endurance	
training	and	re-nutrition	if	required.		Beta-blockers	and	anticholinergic	agents	should	be	
continued	until	the	day	of	surgery	in	all	symptomatic	COPD	patients	with	bronchial	hyper-
reactivity.		In	some	cases,	short-term	systemic/inhaled	steroids	may	be	considered.		
OHS	(obesity,	daytime	hypoventilation,	and	sleep-disordered	breathing)	is	associated	with	
IHD,	heart	failure	(and	obesity-related	cardiomyopathy),	pulmonary	hypertension	and	cor-
pulmonale,	and	increased	perioperative	mortality.		Patients	at	high-risk	of	OHS	who	are	
undergoing	major	surgery	should	be	referred	for	specialist	investigation.		
Pulmonary	arterial	hypertension	(PAH)	(mean	pulmonary	arterial	pressure	>25mmHg	at	
rest)	can	be	primary	or	the	consequence	of	diverse	lung	vascular	or	parenchymal	diseases,	
or	of	cardiac	disease	(e.g.	mitral	valve	disease/intra-cardiac	shunts).		It’s	associated	with	
increased	post-operative	complications,	including	right	ventricular	failure,	myocardial	
ischaemia,	and	post-operative	hypoxia.		Treatment	should	be	optimised	preoperatively,	and	
management	should	be	at	a	centre	with	appropriate	expertise.		Patients	receiving	PAH-
specific	therapy	must	not	have	drugs	withheld	for	the	pre-operative	fasting	state,	and	may	
require	temporary	conversion	to	intravenous	and/or	nebulised	treatment	until	they	are	able	
to	reliably	absorb	via	the	enteral	route.		
	
viii)	Congenital	heart	disease		
Patients	with	congenital	heart	disease	are	at	increased	risk	from	non-	cardiac	surgery,	but	
risk	varies	with	the	degree	of	associated	heart	failure,	pulmonary	hypertension,	arrhythmias	
and	blood	shunting,	and	the	complexity	of	the	underlying	condition.	Complicated	patients	
should	only	undergo	non-cardiac	surgery	after	thorough	evaluation	by	a	multidisciplinary	
team	in	a	specialised	centre.		
	
ix)	Disturbed	glucose	metabolism	&	perioperative	monitoring	
Diabetics	face	greater	perioperative	mortality/morbidity.		Blood	glucose	concentration	
fluctuation	should	be	minimised	and	hypoglycaemia/hyperglycaemia	avoided.		In	the	
intensive	care	unit,	insulin	infusions	should	be	instigated	if		blood	glucose	concentrations	
reach	10.0mMol/l,	with	a	reactive	trigger	at	8.3mMol/l.	Target	concentrations	are	disputed,	
but	those	<6.1mMol/l	are	not	recommended.		
	
SUMMARY	
Both	surgical	and	patient-related	factors	determine	the	risk	of	developing	cardiac	
complications	after	non-cardiac	surgery.		The	extent	of	preoperative	cardiac	evaluation	
must	be	guided	by	a	comprehensive	history	and	examination.	The	risks/benefits	of	delaying	
non-cardiac	surgery	to	optimise	a	patient’s	pathophysiology	must	be	evaluated	case-by-
case,	with	advice	from	other	specialties	where	necessary.		
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